Alam Maroof, Bouillez Audrey, Tagde Ashujit, Ahmad Rehan, Rajabi Hasan, Maeda Takahiro, Hiraki Masayuki, Suzuki Yozo, Kufe Donald
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Mol Cancer Res. 2016 Dec;14(12):1266-1276. doi: 10.1158/1541-7786.MCR-16-0233. Epub 2016 Sep 22.
UNLABELLED: Apical-basal polarity and epithelial integrity are maintained in part by the Crumbs (CRB) complex. The C--terminal subunit of MUC1 (MUC1-C) is a transmembrane protein that is expressed at the apical border of normal epithelial cells and aberrantly at high levels over the entire surface of their transformed counterparts. However, it is not known whether MUC1-C contributes to this loss of polarity that is characteristic of carcinoma cells. Here it is demonstrated that MUC1-C downregulates expression of the Crumbs complex CRB3 protein in triple-negative breast cancer (TNBC) cells. MUC1-C associates with ZEB1 on the CRB3 promoter and represses CRB3 transcription. Notably, CRB3 activates the core kinase cassette of the Hippo pathway, which includes LATS1 and LATS2. In this context, targeting MUC1-C was associated with increased phosphorylation of LATS1, consistent with activation of the Hippo pathway, which is critical for regulating cell contact, tissue repair, proliferation, and apoptosis. Also shown is that MUC1-C--mediated suppression of CRB3 and the Hippo pathway is associated with dephosphorylation and activation of the oncogenic YAP protein. In turn, MUC1-C interacts with YAP, promotes formation of YAP/β-catenin complexes, and induces the WNT target gene MYC. These data support a previously unrecognized pathway in which targeting MUC1-C in TNBC cells (i) induces CRB3 expression, (ii) activates the CRB3-driven Hippo pathway, (iii) inactivates YAP, and thereby (iv) suppresses YAP/β-catenin-mediated induction of MYC expression. IMPLICATIONS: These findings demonstrate a previously unrecognized role for the MUC1-C oncoprotein in the regulation of polarity and the Hippo pathway in breast cancer. Mol Cancer Res; 14(12); 1266-76. ©2016 AACR.
未标记:顶-基极性和上皮完整性部分由Crumbs(CRB)复合体维持。MUC1的C末端亚基(MUC1-C)是一种跨膜蛋白,在正常上皮细胞的顶端边界表达,而在其转化对应物的整个表面异常高水平表达。然而,尚不清楚MUC1-C是否导致癌细胞特有的这种极性丧失。本文证明,MUC1-C在三阴性乳腺癌(TNBC)细胞中下调Crumbs复合体CRB3蛋白的表达。MUC1-C与CRB3启动子上的ZEB1结合并抑制CRB3转录。值得注意的是,CRB3激活Hippo通路的核心激酶盒,其中包括LATS1和LATS2。在这种情况下,靶向MUC1-C与LATS1磷酸化增加有关,这与Hippo通路的激活一致,Hippo通路对调节细胞接触、组织修复、增殖和凋亡至关重要。还表明,MUC1-C介导的对CRB3和Hippo通路的抑制与致癌YAP蛋白的去磷酸化和激活有关。反过来,MUC1-C与YAP相互作用,促进YAP/β-连环蛋白复合物的形成,并诱导WNT靶基因MYC。这些数据支持了一条以前未被认识的途径,即在TNBC细胞中靶向MUC1-C(i)诱导CRB3表达,(ii)激活CRB3驱动的Hippo通路,(iii)使YAP失活,从而(iv)抑制YAP/β-连环蛋白介导的MYC表达诱导。 启示:这些发现证明了MUC1-C癌蛋白在乳腺癌极性调节和Hippo通路中以前未被认识的作用。《分子癌症研究》;14(12);1266 - 76。©2016美国癌症研究协会。
Biomolecules. 2024-3-7
Clin Exp Med. 2023-9
Cancers (Basel). 2022-9-30
Biomolecules. 2022-7-6
J Cancer Metastasis Treat. 2022
Blood. 2016-5-26
Genes Dev. 2016-1-1
Crit Rev Oncol Hematol. 2016-3
PLoS One. 2015-8-12
Clin Cancer Res. 2015-5-15
Oncogene. 2015-10-1